Leela Barham

Leela Barham is a freelance health economist and policy expert. She has published in peer-reviewed journals and presented at national and international conferences. She has provided advice to the Department of Health and Social Care on policy on pricing of branded medicines to inform the negotiation of a successor to the UK’s Pharmaceutical Price Regulation Scheme (PPRS), the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), as well as worked with patient groups, the NHS, pharmaceutical companies and many others internationally on the economics of healthcare and pharmaceuticals. Contact Leela on leels@btinternet.com

Articles

Minimizing the Risk of Mistakes in HTA

We all make mistakes — and that includes those involved in Health Technology Assessment (HTA). Following an error made by ICER this year, Leela Barham looks at similar mistakes made in the past and what can be done about them.

Changing Top Trends in Health Economics and Operational Research

ISPOR has published its third issue of the top trends in HEOR. Leela Barham takes a look at how the list has changed over time.

Putting CADTH on the National and International Stage

Leela Barham talks to Dr. Brian O’Rourke, outgoing President and Chief Executive Officer of the Canadian Agency for Drugs and Technologies in Health (CADTH), about his 11 in years in the role.

ICER Names Drugs with Unsupported Price Increases

Leela Barham reacts to the Institute for Economic and Clinical Review's very first Unsupported Price Increase (UPI) report.

Looking Back at NICE: Sir David Haslam

Leela Barham talks to Sir David Haslam, the outgoing Chair of UK’s National Institute for Health and Care Excellence (NICE), about the highs and lows of his six-year tenure at the organization.

A (New) Tale of Two Pricing Schemes

The UK has had in place what amount to two pricing schemes for branded medicines for years. But with major changes to both schemes set out in 2018, it’s now a new tale of two pricing schemes. Leela Barham reports.

Unsupported Price Increases: A New Focus for ICER

Among the new acronyms watch is UPI, or unjustified price increase, recently coined by ICER as part of its new workstream to explore price increases for both branded and generic drugs in the US.

ICER: Going Global

The Institute for Clinical Effectiveness Review (ICER) has set up a working group to bring together the expertise of NICE and other key HTAs to develop new methods to guide value-based pricing of potential cures. Leela Barham reports.

International Reference Pricing, US Style

President Trump's International Pricing Index proposals amount to international reference pricing (IRP), something that countries in Europe have been doing for years. Leela Barham asks, What lessons can be learned from there?